Chemotherapy targets cancer cells by disrupting DNA replication and mitotic processes, despite side effects on healthy cells.

A recent trial has revealed excessive toxicity, however, in patients receiving a combination of erlotinib (an oral EGFR tyrosine kinase inhibitor) and the standard FOLFIRI chemotherapy regimen.

ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and ...

However, it is imperative to carefully balance the risk of toxicity and functional impairment with survival benefit. Differential Effects of Chemotherapy in Elderly Patients Aging is associated ...

The following is a summary of “Prevalence and outcomes of cancer and treatment-associated toxicities for patients with Ataxia Telangiectasia,” published in the November 2024 issue of Allergy and ...

Sometimes, the drug dose will need to be reduced, or even stopped altogether. There is now a blood test to identify an uncommon DNA gene change that can lead some patients to experience greater ...

Toxicity ≥3 or ≥2 according to CTCAE v2.0 Decreased risk of toxicity for the haplotype 677C-1298C in 5-FU + RT-treated patients Higher risk of diarrhea and mucositis in AA homozygotes treated ...

bevacizumab or placebo every 3 weeks until disease progression or unacceptable toxicity. Combining bevacizumab with chemotherapy considerably improved clinical outcome. Progression-free survival ...

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...

Newer therapies for acute lymphoblastic leukemia target cancer cells more precisely, reducing side effects compared to ...

Chemotherapy during pregnancy is associated with increased morbidity and mortality among infants, reveals study published in ...